January 2012

January 23, 2012


January 10, 2012
By Oka Sarang, Ph.D student of Chemical Engineering I spent the summer of 2011 gaining international experience on two extremely stimulating research projects. I spent the first leg at TU Graz, Graz, Austria, working at the Research Center for 
January 10, 2012
Winning Opportunity in France   By John Lander, Ph.D in Chemical Engineering  
January 10, 2012
Dortmund, Germany: My Global Perspective   By Joseph Tadros, Industrial & Systems Engineering  
January 10, 2012
The China Experience   By Anthony Brown, Bioenvironmental Engineering  

November 2011

November 21, 2011
For Rutgers Entrepreneurship Day, Theta Tau, the co-ed professional engineering fraternity, facilitated the event from start to finish as university staff members.  Members worked all day to make sure that the event progressed smoothly by completing a handful of various tasks. These tasks included set up, greeting, guarding entrances, organizing guests, food distribution, and many more.  Theta Tau also hosted a table near that of the School of Engineering's, which served to publicize what the fraternity
November 10, 2011
November 1, 2011
 Rutgers Command, Control, and Interoperability Center for Advanced Data Analysis (CCICADA), Center for Advanced Infrastructure and Transportation (CAIT), and Center for Discrete Mathematics and Theoretical Computer Science (

October 2011

October 27, 2011
Given annually by the Research and Development Council of New Jersey, the Thomas Alva Edison Patent Awards are offered to tremendous creators and innovators producing work that “supports the advancement of research and development in New Jersey”. Dr. Elsayed A. Elsayed and Dr. Basily B. Basily, both of Industrial Engineering at Rutgers University School of Engineering, are this year’s winners.
October 7, 2011
The National Institutes of Health (NIH) has awarded a Rutgers-affiliated company (Ibris, Inc.) $207,000 to develop a quick and economical analysis of tissue from breast cancer biopsies. The technology is designed to predict how aggressive a common form of breast cancer is likely to be, helping physicians and patients plan effective therapies that minimize side effects.